Seattle Cancer Care Alliance

https://www.seattlecca.org/

 

Myeloma

AML - Keynote - Latest updates on Standard Therapies and Investigational Therapies, MRD in AML, HTC and Non-HCT

Playlist Items:
ASH 2018 AML: Deciding Between Standard vs Investigational Therapies & Problems in Evaluating New Therapies, MRD and HCT, University Of Kansas Cancer Center
ASH December 2018 - MRD in AML - What is the Benefit / Risk Ratio Related to HCT?, University Of Kansas Cancer Center
ASH December 2018 - AML - Allogeneic Hematopoietic Cell Transplantation (HCT) Vs. Non-HCT Consolidation Therapies, University Of Kansas Cancer Center
ASH 2018 AML Challenges in Evaluating New Therapies: Understanding the Recent FDA Approvals, University Of Kansas Cancer Center
  • 444 views
  • March 2019